(NASDAQ: AMGN) Amgen's forecast annual revenue growth rate of 3.33% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.91%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.21%.
Amgen's revenue in 2026 is $36,751,000,000.On average, 37 Wall Street analysts forecast AMGN's revenue for 2026 to be $20,801,004,375,225, with the lowest AMGN revenue forecast at $19,728,259,701,975, and the highest AMGN revenue forecast at $21,819,303,213,300. On average, 34 Wall Street analysts forecast AMGN's revenue for 2027 to be $21,310,962,395,775, with the lowest AMGN revenue forecast at $19,568,695,670,175, and the highest AMGN revenue forecast at $24,003,605,432,400.
In 2028, AMGN is forecast to generate $21,863,506,762,650 in revenue, with the lowest revenue forecast at $19,212,911,004,675 and the highest revenue forecast at $24,969,075,638,325.